Company news
Paradigm Biopharmaceuticals Ltd. (ASX:PAR) news
Paradigm Biopharmaceuticals Ltd. news releases on 6ix. Latest, Sep 30, 2026: Continuation of Suspension from Quotation
Press releases & updates
Continuation of Suspension from Quotation
September 29, 2026
Continuation of Voluntary Suspension
September 27, 2026
Agreement to Return US$2M to Obsidian
September 24, 2026
Phase 3 Interim Result Below Continuation Threshold
September 23, 2026
Suspension from Quotation
September 22, 2026
Appendix 4E and 2026 Annual Report
August 27, 2026
June 2026 Quarterly Activities Report & Appendix 4C
July 29, 2026
Paradigm Receives $5.75m R&D Tax Incentive Refund
July 21, 2026
Drawdown of Tranche 4 under the Convertible Note Facility
July 12, 2026
PAR Completes Enrolment in Pivotal Phase 3
June 14, 2026
Results of Share Purchase Plan
May 31, 2026
DSMB 20% Review Supports Phase 3, Moldova Activated
April 29, 2026
March 2026 Quarterly Activities Report & Appendix 4C
April 27, 2026
Upsized $14M Placement Extends Runway Post IA
April 26, 2026
Paradigm Achieves 50% Patient Dosing in Phase 3
March 30, 2026
Appendix 4D and Half Year Report
February 26, 2026
Drawdown of Tranche 3 under the Convertible Note Facility
February 18, 2026
Published Canine Study Strengthens iPPS Phase 3 Rationale
February 10, 2026
Oral OA Animal Therapy Progresses via AVet Deal
February 8, 2026
December 2025 Quarterly Activities Report & Appendix 4C
January 29, 2026
iPPS Phase 2 Biomarker Results Published in Leading Journal
January 28, 2026
Phase 3 Knee OA Trial Recruitment Update
December 22, 2025
Drawdown of Tranche 2 under the Convertible Note Facility
November 17, 2025
September 2025 Quarterly Activities Report & Appendix 4C
October 29, 2025
Phase 3 Knee OA Trial Recruiting and Dosing in AUS & US
September 30, 2025
Appendix 4E and 2025 Annual Report
August 29, 2025
June 2025 Quarterly Activities Report & Appendix 4C
July 28, 2025
Paradigm Secures US$27M to Advance Phase 3 OA Trial
June 30, 2025
Paradigm Strengthens OA Pipeline with Strategic Acquisition
June 25, 2025
PAR Receives US Ethics Approval for Phase 3
May 14, 2025
March 2025 Quarterly Activities Report & Appendix 4C
April 29, 2025
S&P DJI Announces March 2025 Quarterly Rebalance
March 7, 2025
Paradigm Secures Ethics Approval for Phase 3 Trial
February 23, 2025
Loyalty and Piggyback Options Program
January 31, 2025
PAR Selects Advanced Clinical as CRO for Phase 3
January 30, 2025
Quarterly Activities/Appendix 4C Cash Flow Report
January 30, 2025
Paradigm Receives $6.3m R&D Tax Refund
January 23, 2025
PAR Capital Raising Presentation
December 8, 2024
Successful Completion of $16M Placement for Phase 3
December 8, 2024
Trading Halt
December 4, 2024
Paradigm to Proceed with Phase 3 Knee OA Trial
November 27, 2024
Response to ASX Price Query
November 25, 2024
2024 Chairman Address and AGM Presentation
November 18, 2024
Phase 3 Protocol Submission to US FDA
October 30, 2024
Paradigm Investor Update
October 20, 2024
PAR RECEIVES POSITIVE RESPONSE FROM US FDA FOR PHASE 3
September 17, 2024
Appendix 4E and 2024 Annual Report
August 30, 2024
Type D Response Submitted and Received by the US FDA
April 18, 2024
Half Yearly Report and Accounts
February 28, 2024
Primary Endpoint Achieved in Phase 2 MPS VI Trial
February 8, 2024